(Q35680384)

9 August 2017

1 reference

title

A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. (English)

1 reference

9 August 2017

1 reference

Benjamin J D H Chun

1

1 reference

9 August 2017

David L Dunner

series ordinal

2

1 reference

9 August 2017

publication date

1 February 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

6

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

32-42

1 reference

Secondary mania: manic syndromes associated with antecedent physical illness or drugs

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Can antidepressants cause mania and worsen the course of affective illness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Open trial of fluoxetine in children and adolescents with dysthymic disorder or double depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Fluoxetine in the prevention of depressive recurrences: a double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Moclobemide versus fluoxetine for double depression: a randomized double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Paroxetine pharmacokinetics in depressed children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Possible role of antidepressants in precipitating mania and hypomania in recurrent depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Comparison of St John's wort and imipramine for treating depression: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Common side effects associated with monoamine oxidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Sir John Charles Bucknill 1817-1897: our founder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Safety profile of sustained-release bupropion in depression: results of three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Dysthymic disorder: treatment with mirtazapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Maintenance therapy for chronic depression. A controlled clinical trial of desipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Is bipolar disorder still underdiagnosed? Are antidepressants overutilized?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Strategies to Reduce Misdiagnosis of Bipolar Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Diagnostic reliability of the history of hypomania in bipolar II patients and patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

Systematic clinical methodology for validating bipolar-II disorder: data in mid-stream from a French national multi-site study (EPIDEP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1399-5618.2003.00084.X

10.1046/J.1399-5618.2003.00084.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference